These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31789011)

  • 1. COLCOT and CANTOS: piecing together the puzzle of inflammation and cardiovascular events.
    Wohlford GF; Van Tassell BW; Ravindra K; Abbate A
    Minerva Cardioangiol; 2020 Feb; 68(1):5-8. PubMed ID: 31789011
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
    Liberale L; Montecucco F; Schwarz L; Lüscher TF; Camici GG
    Cardiovasc Res; 2021 Jan; 117(2):411-422. PubMed ID: 32666079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-inflammatory therapy in cardiovascular disease; from hypothesis to future guideline?].
    Hoogeveen RM; Stroes ESG; Cornel JH
    Ned Tijdschr Geneeskd; 2020 Oct; 164():. PubMed ID: 33201620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
    Roman YM; Hernandez AV; White CM
    Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?
    Ridker PM
    Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469
    [No Abstract]   [Full Text] [Related]  

  • 7. Inflammation May be the Future of Cardiovascular Risk Reduction: Does Colchicine have a Current Indication?
    Whayne TF
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):1-10. PubMed ID: 32356107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is colchicine a promising novel treatment option for cardiovascular medicine?
    Imazio M; Gaita F
    Heart; 2016 Apr; 102(8):569-70. PubMed ID: 26839067
    [No Abstract]   [Full Text] [Related]  

  • 9. Inflammation in atherosclerotic cardiovascular disease.
    Shah PK; Lecis D
    F1000Res; 2019; 8():. PubMed ID: 31448091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval.
    Pascart T; Norberciak L; Ea HK; Graf S; Guggenbuhl P; Lioté F
    Rheumatology (Oxford); 2019 Dec; 58(12):2181-2187. PubMed ID: 31177284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from large Cardiovascular Outcome Trials targeting inflammation in cardiovascular disease (CANTOS, CIRT, COLCOT and LoDoCo2).
    Samuel M; Tardif JC
    Future Cardiol; 2021 May; 17(3):411-414. PubMed ID: 33687270
    [No Abstract]   [Full Text] [Related]  

  • 12. [Colchicine treatment after myocardial infarction : Colchicine Cardiovascular Outcomes Trial (COLCOT)].
    Klingenberg R; Nitschmann S
    Internist (Berl); 2020 Jul; 61(7):766-769. PubMed ID: 32103281
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis.
    Hemkens LG; Ewald H; Gloy VL; Arpagaus A; Olu KK; Nidorf M; Glinz D; Nordmann AJ; Briel M
    Heart; 2016 Apr; 102(8):590-6. PubMed ID: 26830663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gout.
    Roddy E; Mallen CD; Doherty M
    BMJ; 2013 Oct; 347():f5648. PubMed ID: 24473446
    [No Abstract]   [Full Text] [Related]  

  • 16. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
    Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
    Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.
    Mehta A; Mahtta D; Gulati M; Sperling LS; Blumenthal RS; Virani SS
    Curr Atheroscler Rep; 2020 Jan; 22(1):3. PubMed ID: 31927694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
    Nidorf SM; Thompson PL
    Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for cardiovascular disease.
    Lutgens E; Atzler D; Döring Y; Duchene J; Steffens S; Weber C
    Eur Heart J; 2019 Dec; 40(48):3937-3946. PubMed ID: 31121017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk.
    Ait-Oufella H; Libby P; Tedgui A
    Arterioscler Thromb Vasc Biol; 2019 Aug; 39(8):1510-1519. PubMed ID: 31294625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.